Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia

Liu Zhi-gao; Yu Xi-yong

doi:10.1007/BF02836425

Your Location：

Home >

Browse articles >

Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia

OriginalPaper | Updated：2021-08-27

- Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia
- Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia
- 中国结合医学杂志（英文版） 2004年10卷第4期页码：259-262
- Affiliations：
  
  1. Department of Cardiology, Affiliated Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan
  2. Guangdong Provincial Institute of Cardiovascular Diseases,Guangzhou
- Author bio：
- Funds：
- DOI：10.1007/BF02836425
  中图分类号：
- 纸质出版日期：2004，
Scan for full text
Zhi-gao, L., Xi-yong, Y. Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia., Chin. J. Integr. Med. 10, 259–262 (2004). https://doi.org/10.1007/BF02836425

Liu Zhi-gao, Yu Xi-yong. Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia[J]. Chinese Journal of Integrative Medicine, 2004,10(4):259-262.
Zhi-gao, L., Xi-yong, Y. Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia., Chin. J. Integr. Med. 10, 259–262 (2004). https://doi.org/10.1007/BF02836425 DOI：

Liu Zhi-gao, Yu Xi-yong. Effects of Xuezhikang capsule on blood lipids, platelet activation and coagulation-fibrinolysis activity in patients with hyperlipidemia[J]. Chinese Journal of Integrative Medicine, 2004,10(4):259-262. DOI： 10.1007/BF02836425.

摘要

Objective: To investigate the effects of Xuezhikang capsule (XZK) on blood lipids level

platelet activation and coagulation-fibrinolysis activity in patients with hyerlipidemia.Methods: Seventy-six patients of hyperlipidemia were randomly divided into two groups

the XZK group (n = 38) treated with XZK 600mg

taken two times per day and the Simvastatin (SIM) group (n = 38) treated with SIM 20mg per day

with the treatment lasting 8 weeks for both groups. Levels of fasting serum lipids

including total cholesterol (TC)

triglyceride (TG)

high and low density lipoprotein cholesterol (HDL-C and LDL-C)

plasma GMP-140

fibrinogen (FIB)

tissue plasminogen activator (t-PA)

plasminogen activator inhibitor type-1 (PAI-) and prothrombin time (PT) were all measured before and 8 weeks after treatment. Data were compared before and after treatment and also compared with those measured in 20 healthy subjects of control.Results: Before treantment the levels of TC

TG and LDL-C were obviously higher and HDL-C level was significantly lower in hyperlipidemia patients than those in healthy subjects (P<0.05 orP<0.01). After 4–8 weeks of XZK treatment

the levels of TC

LDL-C and FIB and activities of GMP-140 and PAI-1 were obviously lowered (P<0.05 orP<0.01). But in the SIM group there was no obvious change in FIB (P>0.05)

instead it showed obvious increase of HDL-C and decrease of TC and LDL-C after treatment (P<0.05 orP<0.01).Conclusion: XZK could inhibit platelet activity and improve coagulation-fibrinolysis function

besides its lipids lowering effect.

Abstract

Objective: To investigate the effects of Xuezhikang capsule (XZK) on blood lipids level

platelet activation and coagulation-fibrinolysis activity in patients with hyerlipidemia.Methods: Seventy-six patients of hyperlipidemia were randomly divided into two groups

the XZK group (n = 38) treated with XZK 600mg

taken two times per day and the Simvastatin (SIM) group (n = 38) treated with SIM 20mg per day

with the treatment lasting 8 weeks for both groups. Levels of fasting serum lipids

including total cholesterol (TC)

triglyceride (TG)

high and low density lipoprotein cholesterol (HDL-C and LDL-C)

plasma GMP-140

fibrinogen (FIB)

tissue plasminogen activator (t-PA)

TG and LDL-C were obviously higher and HDL-C level was significantly lower in hyperlipidemia patients than those in healthy subjects (P<0.05 orP<0.01). After 4–8 weeks of XZK treatment

the levels of TC

LDL-C and FIB and activities of GMP-140 and PAI-1 were obviously lowered (P<0.05 orP<0.01). But in the SIM group there was no obvious change in FIB (P>0.05)

besides its lipids lowering effect.

关键词

Xuezhikang capsuleSimvastatinhyperlipidemiaplatelet α-granule membrane glycoproteincoagulation-fibrinolysis

Keywords

Xuezhikang capsuleSimvastatinhyperlipidemiaplatelet α-granule membrane glycoproteincoagulation-fibrinolysis

references

Tremoli E, Cllis S, Maderma P, et al. Hypercholesterolemia and platelets. Semin Thromb Haemost 1993; 19: 115–120.

Joukhadar C, Klein N, Prinz M, et al. Related articles: Similar effects of atorvastatin, simvastatin and prevastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85(1): 47–51.

Special Group for Prevention and Treatment of Blood Lipids Abnormality, editor board of Chinese Journal of Cardiology. Proposal on prevention and treatment of abnormal blood lipids. Chin J Cardiol 1997; 25(3): 169–175.

Wu GX, Li JY, Li PX, et al. Radioimmune detection of α-granule membrane glycoprotein on surface of platelets and blood plasma. Chin J Hematol 1992; 13(2): 99–101.

Aviran M, Osamah H, Mira R. Interactions of platelets macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA-reductase inhibitor therapy. Cardiovasc Pharmacol 1998; 31(1): 39–45.

Galle J, Bassenge E, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res 1990; 66(1): 1287–1293.

Rosenson BR, Tangney CL. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279(11): 1643–1650.

Sun Y, Bai Y. Blood lipids regulating effects of statins. Adv in Cardiovasc Dis 2003; 24(1): 4–7.

Allan ML, Rosario Scalia, David JL. Vascular effects of HMG-CoA-reductase inhibitors(statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281–287.

Catherin L, David E, Newby H, et al. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res 2000; 47: 707–714.

FULL TEXT LINK

More>

浏览量

395

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effect of Xuezhikang Capsule (血脂康胶囊) on serum tumor necrosis factor-α and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia

Effect of Taizhi’an capsule combined with Simvastatin on hyperlipidemia in diabetic patients

Study on effect of Zhixinkang Capsule in treating unstable effort angina and hyperlipidemia and its function in vascular endothelium protection

Effect of theo-polyphenols on hepatic histology of hyperlipidemia model in quails

Effect of astragalus- angelica mixture on lipoprotein lipase and lecithin- cholesterol acyltransferase of nephrotic rats